Tags

Type your tag names separated by a space and hit enter

Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease.
Curr Pharm Des. 2010; 16(25):2790-8.CP

Abstract

Originally discovered because of its role in the regulation of glucose metabolism, Glycogen Synthase Kinase-3 (GSK-3) it is now recognised as a crucial player in a diverse series of cellular processes involved in Alzheimer's disease (AD) pathology. Besides having been identified as the major tau protein kinase, GSK-3 mediates Aβ neurotoxicity, plays an essential role in synaptic plasticity and memory, might be involved in Aβ formation, and it has an important role in inflammation and neuronal survival, all key features of AD neuropathology. Moreover, AD was one of the earliest disorders linked to GSK-3 dysfunction. Thus, the discovery of small molecule GSK-3 inhibitors has attracted significant attention to the protein both as therapeutic target for the therapeutic intervention in neurodegenerative diseases as well as a means to understand the molecular basis of these disorders.

Links

Aggregator Full Text

Authors+Show Affiliations

Medina M
Noscira S.A, Avenida de Industria 52, 28760 Tres Cantos (Madrid), Spain.
Avila J
No affiliation info available

MeSH

Alzheimer DiseaseAnimalsDrug Delivery SystemsGlycogen Synthase Kinase 3HumansLithium CompoundsModels, BiologicalNerve DegenerationProtein Kinase Inhibitors

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

20698823

Citation

Medina, Miguel, and Jesús Avila. "Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimer's Disease." Current Pharmaceutical Design, vol. 16, no. 25, 2010, pp. 2790-8.
Medina M, Avila J. Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. Curr Pharm Des. 2010;16(25):2790-8.
Medina, M., & Avila, J. (2010). Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. Current Pharmaceutical Design, 16(25), 2790-8.
Medina M, Avila J. Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimer's Disease. Curr Pharm Des. 2010;16(25):2790-8. PubMed PMID: 20698823.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. AU - Medina,Miguel, AU - Avila,Jesús, PY - 2010/07/09/received PY - 2010/07/21/accepted PY - 2010/8/12/entrez PY - 2010/8/12/pubmed PY - 2011/2/9/medline SP - 2790 EP - 8 JF - Current pharmaceutical design JO - Curr Pharm Des VL - 16 IS - 25 N2 - Originally discovered because of its role in the regulation of glucose metabolism, Glycogen Synthase Kinase-3 (GSK-3) it is now recognised as a crucial player in a diverse series of cellular processes involved in Alzheimer's disease (AD) pathology. Besides having been identified as the major tau protein kinase, GSK-3 mediates Aβ neurotoxicity, plays an essential role in synaptic plasticity and memory, might be involved in Aβ formation, and it has an important role in inflammation and neuronal survival, all key features of AD neuropathology. Moreover, AD was one of the earliest disorders linked to GSK-3 dysfunction. Thus, the discovery of small molecule GSK-3 inhibitors has attracted significant attention to the protein both as therapeutic target for the therapeutic intervention in neurodegenerative diseases as well as a means to understand the molecular basis of these disorders. SN - 1873-4286 UR - https://www.unboundmedicine.com/medline/citation/20698823/Glycogen_synthase_kinase_3__GSK_3__inhibitors_for_the_treatment_of_Alzheimer's_disease_ L2 - https://www.ingentaconnect.com/openurl?genre=article&issn=1381-6128&volume=16&issue=25&spage=2790&aulast=Medina DB - PRIME DP - Unbound Medicine ER -